People are notoriously poor at making decisions based on complex uncertain data when there is a lot at stake. When human biases distort drug discovery decision-making, software tools can guide thinking towards objective answers.
Given the high cost of moving a promising drug candidate through years of clinical trials, it’s no wonder that more and more drug and device manufacturers have begun conducting at least some of their clinical trials in foreign countries.
In order to get a better picture of the drug research market, the editors recently surveyed Drug Discovery & Development readers to measure interests, concerns, and research trends. Some results were quite predictable. Others were a little surprising. Read the opinions, and add your own.
Tracking specific components in complex samples plays a fundamental role in many aspects of modern drug discovery and development. To simultaneously measure multiple cell parameters, researchers can combine flow cytometry and multi-color antibody kits.
It’s the drug developer’s nightmare: the compound that looked great in early screens turns out to be toxic in an expensive animal model—or worse, in clinical trials. Can a new generation of cellular assays come to the rescue?
Beckman Coulter will now refer customers seeking particle characterization services to ImmunoSite Technologies and ImmunoSite will perform those services using Beckman Coulter particle characterization instrumentation.
Targestar P-HF, a perfusion contrast agent specifically designed to be used with high frequency ultrasound scanners, is restricted to the vascular compartment and enables visualization of the vasculature and quantification of blood flow in animal studies.
A few unassuming drops of liquid locked in a very precise game of "follow the leader" could one day be found in mobile phone cameras, medical imaging equipment, implantable drug delivery devices, and even implantable eye lenses.
Researchers report a gene therapy strategy that improves the condition of a mouse model of an inherited blood disorder, Beta Thalassemia. The gene correction involves using unfertilized eggs from afflicted mice to produce a batch of embryonic stem cell lines.
Camargo Pharmaceutical Services, a full-service clinical research organization specializing in end-to-end drug development, has announced the company’s appointment of Ray Dawkins, MD, as chief medical officer.
Nikon Instruments Inc., an innovator of advanced optical instruments, announced an agreement with Agilent Technologies, a technology leader in chemical analysis and life sciences, for distribution in the Americas of Agilent's MLC400 monolithic laser combiner systems.
InSite Vision Incorporated announced that it has filed an Investigational New Drug application for ISV-101 with the U.S. Food and Drug Administration. ISV-101 is InSite Vision's novel compound being developed to treat dry eye disease.
Merck announced that the new drug application for the company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration.
British orthopedic maker Smith & Nephew has reportedly rejected an acquisition offer from U.S. health care giant Johnson & Johnson. Britain's Sky News reported that Smith & Nephew had rejected an offer valued at 7 billion pounds, or nearly $10.9 billion.
Bristol-Myers Squibb Co. and Pharmasset Inc. said they will run a clinical trial testing the combination of two hepatitis C drugs, one developed by each company. Pharmasset is developing PSI-7977, while Bristol-Myers Squibb's drug is designated BMS-790052.